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Purpose: The aim of this study was to investigate possible association between
high-risk Human papillomavirus (HR HPV) – induced cervical infection, HR
HPV-related cervical dysplasia, HR HPV genotypes with two Toll-like receptor
(TLR) 9 gene polymorphisms and other risk factors.
Methods: During a three-year period, 100 women positive for cervical HR HPV
infection (97 with cervical dysplasia and 3 positive women without dysplasia)
were genotyped using the Linear Array HPV Genotyping assay (Roche Diag-
nostics). Furthermore, two polymorphisms of TLR9 (-1486T/C, rs187084 and
2848C/T rs352140) were determined using real-time Polymerase Chain Reaction;
50 HR HPV negative women of similar ethnicity were included as controls.
Results: This study showed that infections with HPV 16 in women with cervi-
cal dysplasia were more frequently found compared with HPV 18 infections
(p=0.0539). Comparison between HR HPV positive and negative women
showed significant association between age >35 years (p=0.0058), being un-
married women (p=0.0001), nocondom usage (p=0.0304) and active tobacco
smoking (p=0.0376) with HR HPV cervical infection. No significant associa-
tions between two TLR9 gene polymorphisms, HR HPV infection and cervical
dysplasia were found.
Conclusion: Our results indicated that: i) women with cervical dysplasia
showed significant higher rate of HR HPV 16 infection compared to HR HPV
18, ii) HR HPV – infection was strongly correlated with social risk factors and iii)
TLR9 gene polymorphisms (rs187084; rs352140) did not correlate with HR HPV
infection and cervical dysplasia. Further genome-wide association studies could
open new frontier in understanding the relationship between polymorphisms at
TLR9 and immunological mechanisms in HPV-induced carcinogenesis.
Izvorni znanstveni rad
Cilj: Cilj ovog istra`ivanja bio je utvrditi povezanost izme|u infekcije vrata
maternice visokorizi~nim humanim papilomavirusima (engl. high-risk Human
papillomavirus – HR HPV), displazije vrata maternice uzrokovane visokori-
zi~nim genotipovima HPV-a, visokorizi~nih genotipova HPV-a te dva polimor-
fizma gena za Toll-u sli~an receptor (TLR) 9 i drugih rizi~nih ~imbenika.
Metode: Tijekom trogodi{njeg razdoblja, u 100 ` ena s cervikalnom infekcijom
visokorizi~nim genotipovima HPV-a (97 s displazijom vrata maternice i 3 s pozi-
tivnim nalazom HPV-a ali bez displazije vrata maternice) odre|eni su genoti-
povi virusa primjenom molekularnog testa Linear Array HPV Genotyping assay
(Roche Diagnostics). Tako|er su analizirana i dva polimorfizma gena za TLR9
(-1486T/C, rs187084 i 2848C/T rs352140) koriste}i metodu lan~ane reakcije
polimerazom u stvarnom vremenu; te je 50 `ena s negativnim HR HPV ili
sli~nog etniciteta uklju~eno kao kontrolna skupina.
Rezultati: Istra`ivanje je pokazalo da su HR HPV infekcije genotipom 16 ~e{}e
u `ena sa displazijom vrata maternice u usporedbi sa `enama s infekcijom
genotipa 18 (p=0.0539). Usporedbom `ena s pozitivnim i negativnim nalazom
na HR HPV, utvr|ena je zna~ajna povezanost izme|u dobi >35 godina
(p=0.0058), bra~nog statusa (slobodne osobe, p=0.0001), nekori{tenja kondo-
ma (p=0.0304) i aktivnog pu{enja (p=0.0376) i infekcije s HR HPV. Poveza-
nost izme|u dva polimorfizma gena za TLR9, infekcije HR HPV i displazije
vrata maternice nije dokazana. 
Zaklju~ak: Rezultati ovog istra`ivanja pokazali su da: i) je u `ena sa displazi-
jom vrata maternice zna~ajno ve}a u~estalost infekcije s genotipom 16 u us-
poredbi s genotipom 18, ii) infekcija s HR HPV povezana je sa socijalnim fak-
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TLR9 cytidine-phosphateguanosine (CpG)-rich dsDNA.
The activation of these receptors results in production of
cytokines and creates a powerful pro-inflammatory envi-
ronment. For example, activation of TLR9 in keratino-
cytes results in production of tumor necrosis factor alpha
(TNF-α), interleukin-8 (IL8), type I interferon (IFN). The
main TLR in relation to dsDNA virus infection is TLR9
[6]. Combinations of PAMPs that trigger TLR3 and TLR4
in synergy with TLR7, TLR8 and TLR9 were shown to
trigger vigorous type 1 immunity, showing immunological
advantages of engaging multiple TLRs. The viruses are de-
tected by TLRs in dendritic cells (DC) first, by the surface
TLR2 interacting with the virions, and second, by the in-
tracellular TLR9 recognizing the viral DNA [7]. HPV acti-
vates TLR7 and stimulates dendritic cells to produce Th1-
type immune response against HPV infection. Alteration
in oncogenes, tumor suppressor genes, or abnormal cell
adhesion molecules in the TLR-mediated signaling path-
way, can lead to inappropriate activation and carcinogene-
sis, which is possible complication of HPV infection. In
addition to their function of activating immune response,
TLRs establish a suitable microenvironment for tumor cell
growth, which allows tumor cells to evade immune cells,
infiltrate, metastasize, and undergo malignant progres-
sion. Moreover, TLRs promote tumor cell proliferation
and malignant biological behavior by inducing anti-apop-
totic protein expression [4]. The final outcome of infection
is different for different hosts and different types of HPV.
For example, the HPV oncogenes, E6 and E7 are able to
block TLR9-induced cytokine secretion by human
keratinocytes [8]. The CpG sequences of E6 and E7 HPV
oncogenes, can bind to TLR9 and reduce the viral clear-
ance capability of the host, contributing to persistent infec-
tion. TLR9 can also promote tumor cells to secrete a vari-
ety of cytokines and cell adhesion molecules, increase tu-
mor cell adhesion and invasion, promote tumor cell
growth and inhibit tumor cell apoptosis. Even more, TLR9
can induce immune inhibitor production and restrain the
attack of cytotoxic lymphocytes on tumor cells, therefore
leading to immune escape [4]. HPV 16 is the most carcino-
genic type among high risk (HR) sub-group and interferes
with innate immunity by affecting the expression of TLRs
[9]. Also, HPV 16 is able to evade immune recognition and
this evasion results in its persistence. TLRs whose change
in expression is significantly different between women
with HPV clearance and those with persistence are TLR2,
TLR3, TLR7, TLR8 and TLR9 [5]. Infection of human pri-
mary keratinocytes with HPV 16 E6 and E7 inhibits TLR9
transcription and consequently leads to functional loss of
TLR9-regulated pathways. However, E6 and E7 from low
Introduction
Human papilloma virus (HPV) is one of the most com-
mon causes of sexually transmitted diseases worldwide
[1]. In Croatia with population of 4.4 million, 355 new
cases of cervical cancer and about 100 deaths are regis-
tered each year [2]. Recent studies have established the
central role of humoral immunity to prevent HPV infec-
tion. Duration and elimination of HPV is related to innate
immunity [1] although most of infections are asympto-
matic and spontaneously resolve in 12 – 18 months [3].
Differently abled innate immunity disrupt the clearance of
HPV which cause long-term cervical infection that may
progress to malignant lesion [1]. Cells in innate immune
system can recognize pattern recognition receptors
(PRRs) and pathogen-associated molecular patterns
(PAMPs). Toll-like receptors (TLR) as cellular transmem-
brane PRRs and PAMP receptors have an important role in
innate immunity. By recognizing different PAMPs, TLRs
generate immune responses to destroy pathogens. At pre-
sent members of human TLR family, including TLR2,
TLR3, TLR4, TLR7, TLR8 and TLR9 have been identi-
fied to recognize viruses [4]. TLRs are present on numer-
ous cell types and have the ability to detect and bind dif-
ferent pathogen-associated molecules. This reaction sig-
nals the presence of an invading microbe and starts a di-
rect immune response against it. Ligation of TLRs leads to
expression of effector molecules, such as pro-inflammato-
ry and immune-mediating cytokines. Ten TLRs have been
identified in man and several have been shown to be im-
portant for detection of viruses. TLR3, TLR7, TLR8 and
TLR9 are localized intracellularly, where they sense the
presence of viral nucleic acid. Also, cell surface-expres-
sed TLR2 and TLR4 interact with viral proteins; however
the consequence for the host are less clear [5]. At the be-
ginning of HPV infection, the innate immune system cre-
ates a proinflammatory microenvironment by recruiting
innate immune cells to eliminate the infected cells. To pre-
vent such outcome, HPV express a wide range of strate-
gies for evading immune-surveillance, generating an anti-
inflammatory microenvironment. HPV infects keratino-
cytes in the cervical epithelium and probably stem cells.
The keratinocytes represent immune sentinels of the in-
nate immune defense system. They express several TLRs
located on the cell surface (TLR1, TLR2, TLR 4, TLR5,
TLR6) or in the endosomes (TLR3, TLR9). Endosomal
TLRs have an important role in combating viral infection
and in recognition of viral nucleic acids; TLR3 recognizes
double-stranded deoxyribonucleic acid (dsDNA), TLR7
and TLR8 single-stranded ribonucleic acid (ssRNA), and
torima rizika i iii) polimorfizmi gena za TLR9 (rs187084;
rs352140) nisu povezani s HR HPV infekcijom i displazijom
vrata maternice. Daljnja genomska istra`ivanja mogu pro{iriti
spoznaje u razumijevanju odnosa izme|u polimorfizma gena za
TLR9 i imunolo{kih mehanizama u HPV-om induciranoj kar-
cinogenezi.
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risk (LR) HPV subtypes are unable to downregulate the
TLR9 promoter. In addition, E6 and E7 from HPV 18,
which is known to persist less competently in the host than
HPV 16, have reduced efficiency compared with HPV 16
in inhibiting TLR9 transcription. Abolishing innate re-
sponses may be crucial step involved in the carcinogenic
events mediated by HPVs [9]. Activation of TLR9 path-
way by CpG pattern is reduced severely in human ker-
atinocytes expressing HPV 16 E6 and E7 oncoproteins.
This event is due to the ability of the viral oncoproteins to
down-regulate TLR9 mRNA. TLR9 promoter down-reg-
ulation is less significant for HPV 18 compared with HPV
16 and is completely absent in cells expressing E6 and E7
in LR HPVs. In this way, the efficiency of HPV 16 in per-
sistent infection appears to correlate with its ability to
downregulate the transcription of TLR9. HPV 16 use
TLR9 deregulation as a strategy to avoid viral recognition
and has ability to interfere with the first response to infec-
tion agents via TLRs. HPV 16 E6 and E7 directly inhibit
TLR9-mediated pathways by down-regulating the tran-
scription of the TLR9 gene. The mechanism by which vi-
ral CpG-DNA pattern enter the endosomal compartment,
where TLR9 is expressed, is presently unclear. It is specu-
lated that, during infection, disassembly of the viral capsid
in the endosome results in viral DNA release and this may
initiate TLR9 signaling [9]. Akey result of TLR activation
is release of proinflammatory and immune-mediating cy-
tokines, of which IFN-α2 is considered the most immedi-
ate product of TLR activation. It is clear that increase in
TLR expression in cervical samples with incident HPV 16
infection is associated with viral clearance and lack of
with increased persistence [5]. The ability of TLR9 to in-
hibit HPV induced carcinogenesis has recently been ac-
centuate by the fact that specific TLR9 polymorphisms
are associated with an increased risk of cervical cancer
among women [8]. A growing amount of evidence sug-
gests that single nucleotide polymorphisms (SNP) in TLR
genes are enough to decrease the ability to respond prop-
erly to infection [10]. Based upon those findings and un-
explainable nature of different immune responses in HPV
infections, we investigate whether TLR9 rs187084 and
TLR9 rs352140 polymorphisms correlate with suscepti-
bility to HPV infection.
Materials and Methods
Study population
This cross-sectional study included 100 HR HPV pos-
itive women and 50 HR HPV negative women from
Osijek-Baranja County tested for sexually transmitted
diseases (STDs) between March 2009 and December
2011. The mean age of HR HPV positive women was
28±7.2 years (ages 18 to 56) while of HR HPV negative
women was 34±9.3 (ages 18 to 60). All women were re-
ferred to our department by their gynecologists and the in-
formation about their cervical intraepithelial neoplasia
(CIN) was obtained from gynecologist's questionnaires.
Informed consent was obtained from all HR HPV ana-
lyzed patients. Participants completed a questionnaire that
included questions on marital and socio-economic status,
education level, sexual and smoking habits. Eight incom-
plete questionnaires were excluded from the statistical
analyses of lifestyle risk factors associated with HPV gen-
ital infection. The inclusion criteria in sample formation
were adult females (>–18 years), sexually active and exclu-
sion criteria juvenile participant (<18 years), sexually in-
active, incomplete informed consent. The study was ap-
proved by the Ethics Committee of the Institute of Public
Health of Osijek-Baranja County and performed accord-
ing to ethical principles of the 1975 – 1983 Helsinki decla-
rations.
HR HPV detection
DNA was isolated using the High Pure PCR Template
Kit and analyzed for the presence of HR HPV by the AM-
PLICOR HPV test (Roche Diagnostics, Germany) ac-
cording to the manufacturer's instructions. DNA from




The HR HPV positive cervical samples were geno-
typed by the Linear Array HPV Genotyping Test (Roche
Diagnostics, Germany). This test detects 37 HR, inter-me-
diate risk (IR) and LR HPV genotypes (HPV 6, 11, 16, 18,
26, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 54, 55, 56, 58, 59,
61, 62, 64, 66, 67, 68, 69, 70, 71, 72, 73, 81, 82, 83, IS39
and CP6108). It is based on the Polymerase Chain React-
ion (PCR)-based amplification of polymorphic L1 region,
hybridization to the HPV probes and colorimetric visual-
ization. As internal control, test amplifies beta-globin
gene to asses cellular adequacy, extraction and amplifica-
tion for each processed specimen.
Detection of TLR polymorphisms
Blood was collected using EDTA – vacutainer and
whole genomic DNA was extracted and purified using a
spincolumn based method according to the manufacturer's
instruction (High Pure PCR Template Kit, Roche
Diagnostics, Germany). DNA was stored at –20 °C for
further analysis.
TLR9 polymorphisms were performed using pre-es-
tablished LightSNiP assay designed by Tib MolBiol (Tib
MolBiol Syntheselabor GmbH, Germany) as followed:
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1. TLR9 (rs352140) SNP, allele C/T. PCR was per-
formed using 3 μl DNA, 0.5 μM TLR9 primers (forward
5'– GCATCTCGCAGGCAGTCA – 3', reverse 5' –
CACGCCCTGCATGCCAA – 3'), 0.225 μM TLR9 sensor
probe (5' – TTCACGGAGCTACCACGACTG – 3'),
0.225 μM TLR9 anchor probe (640 – 5' – GCCCTGGAC-
CTCAGCTACAACAGCC – 3'), 3.0 mM MgCl 2, and
Light Cycler FastStart DNA mastermix in a total volume
of 20 μl. The PCR was performed using LightCycler 1.5
version at following conditions: initial denaturation step
(95 °C for 10 min), 40 cycles consisted of denaturation (95 °C
for 10 s), annealing (54 °C for 15 s) and extension (72 °C
for 25 s). The melting curve analysis involved 1 cycle at
95 °C for 20 s and 40 °C for 20 s, followed by an increase
of temperature to 85 °C at a slope of 0.2 °C/s. Melting tem-
perature values were graphically represented as the nega-
tive first derivative of the change in fluorescence with tem-
perature (-dF/dT). The C allele of TLR9 rs352140 had a
melting peak of 60.1 °C, while T allele had a melting peak
of 68.0 °C.
2. TLR9 (rs187084) SNP, allele T/C. PCR was per-
formed using 5 μl DNA, 0.5 μM TLR9 primers (forward 
5'– ACCCCAGATCTGGCACTCCCTGAGC – 3', re-
verse 5' – GCCCAGAGCTGACCTGCTGGGTGTAC –
3'), 0.225 μM TLR9 sensor probe (5' – GAATGTCAGCT-
TCTTAAGGGCA – 3'), 0.225 μM TLR9 anchor probe
(640 – 5' – TGATCTTTTATCTGCATCCCCAGGATC –
3'), 2.5 mM MgCl 2, and Light Cycler FastStart DNAmas-
termix in a total volume of 20 μl. The PCR was performed
using LightCycler 1.5 version at following conditions: ini-
tial denaturation step (95 °C for 10 min), 40 cycles consist-
ed of denaturation (95 °C for 10 s), annealing (60 °C for
10 s) and extension (72 °C for 15 s). The melting curve
analysis involved 1 cycle at 95 °C for 20 s and 40 °C for
20 s, followed by an increase of temperature to 85 °C at a
slope of 0.2 °C/s. Melting temperature values were graph-
ically represented as the negative first derivative of the
change in fluorescence with temperature (-dF/dT). The C
allele of TLR9 rs187084 had a melting peak of 62.21 °C,
while T allele had a melting peak of 67.1 °C.
Statistical analysis
All participants in this study were classified according
to their age into two groups: between 18 and 35 years and
above 35 years and HR HPV positive and negative infec-
tion. A χ2 test was used for the analysis of age groups,
smoking habits, marital status, number of sexual partners,
condom usage, monthly income, chronic illness status and
daily dose of drugs and distribution of HR HPV infection.
The same statistical test was used to analyze the difference
between TLR9 rs187084 and TLR9 rs352140, age groups,
smoking habits and Pap smear results (CIN1-3, carcinoma
in situ). To test associations between three genetic variants
of TLR9 rs187084, three genetic variants of TLR9
rs352140 and distribution of the HR HPV infection χ2 was
used. The χ2 and FisherFreeman-Halton tests were used to
determine the difference between three TLR9 rs187084
genotypes distributions in HR HPV women and HR HPV
negative women as well as between three TLR9 rs352140
genotypes distributions in HR HPV positive women and
HR HPV negative women.
The nonparametric Mann-Whitney U test was used to
compare the distribution of two variables. The magnitude
of association between TLR polymorphisms and HR HPV
infection was expressed as an odds ratio (OR) with a 95 %
confidence interval (95 % CI). The Hardy-Weinberg test of
the equilibrium of genotype frequencies was performed
using the exact test (HWsim program, 50000 Monte Carlo
simulation steps). The linkage disequilibrium Lewontin
coefficients D' and r2 were calculated to reflect allelic link-
age (Haploview program http://www.broadinstitute.org).
All differences were considered to be significant at
p<0.05. The Statistica 12.0 software, MedCalc Version
10.2.0.0. and Microsoft Office Excel 2003 (Microsoft)
programs were used for statistical analyses.
Results
Distribution of HR HPV infection according to risk
factors
Analysis of the HR HPV-related risk factors such as
age, marital status, number of sexual partner, monthly in-
come, active tobacco smoking and distribution of HR HPV
cervical infection in north-east Croatia present significant
differences between HR HPV positive and negative
women in four risk factors. Table 1 shows that HR HPV in-
fections were more prevalent in 18 – 35 year old women
than in women older than 35 years of age (p=0.0058).
Moreover, HR HPV infections were significant higher in un-
married women compared to married women (p=0.0001).
The no condom use (p=0.0304) and active tobacco smok-
ing (p=0.0376) were significant associated with HR HPV
positive infections compared to HR HPV negative women.
On the other hand, no significant association was found
between: number of sexual partners, working status,
monthly income, other chronically diseases, and daily
medicament use with HR HPV infections.
Distribution of two SNPs of TLR9 gene in HR HPV
positive women and HR HPV negative women
Comparison of distribution of six genetic variants
within two polymorphisms of TLR9 (-1486T/C, rs187084
and 2848C/T rs352140) between 100 HR HPV positive
and 50 negative women show no significant associations
between investigeted polymorphisms, HR HPV infection
and cervical dysplasia (Table 2).
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N (%) OR [95 % CI]* p-value
Age (years) 







0.34 [0.15; 0.74] 0.0058 








0.23 [0.11; 0.49] 0.0001 












































2.09 [0.43; 10.22] 0.3545 








2.08 [1.04; 4.16] 0.0376 
Table 1. Statistical analysis of potential risk factors for HR HPV cervical infection
Tablica 1. Statisti~ka analiza potencijalnih ~imbenika rizika za HR HPV infekciju vrata maternice
cervical dysplasia TLR9 (rs187084)
p-value χ2
CC (%) CT/TT (%)
negative 18 (12) 35 (23.3)
0.8365 0.043positive 36 (24) 61 (40.7)
total 54 (36) 96 (64)
TLR9 (rs352140)
negative 17 (11.3) 36 (24)
0.9272 0.008positive 29 (19.3) 68 (45.3)
total 46 (30.7) 104 (69.3)
Table 2. Distribution of two alleles carriers of TLR9 polymorphisms (rs187084 and rs352140) according to the cervical dysplasia
Tablica 2. Raspodjela dva alela nosa~a TLR9 polimorfizama (rs187084 and rs352140) prema cervikalnoj displaziji
* OR, odds ratio; CI, confidence interval; ** reference 
HPV genotype CC (wt
a)
N = 37 
TT (mtb) 
N = 63 p-value χ
2
mixed 16 27 0.9748 0.001 
16 9 12 0.6150 0.253 
18 0 2 0.2813 1.161 
31 3 3 0.5235 0.407 
51 3 2 0.3014 1.068 
52 2 3 0.8933 0.018 
58 0 3 0.1882 1.732 
Table 3. HPV genotypes distribution according to TLR9 polymorphism (rs187084)
Tablica 3. Raspodjela HPV genotipova prema TLR9 polimorfizmu (rs187084)
awt-wild type; bmt-mutation type 
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Distribution of two SNPs of TLR9 gene according to
HPV genotypes in HR HPV positive women
Table 3 and 4 show no association between HPV geno-
types (HPV 16, 18, 31, 51, 52, 58 and mixed HR HPV in-
fection) and two polymorphisms of TLR9 (-1486T/C,
rs187084 and 2848C/T rs352140).
Distribution of cervical dysplasia CIN1-CIN3 ac-
cording to HPV 16 and HPV 18 cervical infection
Table 5 compares the distribution of three stage of cer-
vical dysplasia (CIN1-CIN3) between number of HPV 16
and HPV 18 infections. Significant difference was found
between HPV 16 and HPV 18 cervical infections accord-
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HPV genotype CC (wt
a) 






mixed 13 11 19 0.9517 0.099 
16 7 7 7 0.7573 0.556 
18 1 0 1 0.6544 0.848 
31 3 2 1 0.4317 1.68 
51 0 3 2 0.2064 3.156 
52 3 0 2 0.2506 2.768 
58 0 1 2 0.5107 1.344 
Table 4. HPV genotypes distribution according to TLR9 polymorphism (rs352140)
Tablica 4. Raspodjela HPV genotipova prema TLR9 polimorfizmu (rs352140)
awt-wild type; bmt-mutation  type; cht-heterozygous type 
No. of cases (single or mixed infection) CIN 1 CIN 2 CIN 3 p-value χ2
16 13 8 13
0.0539 5.839 
18 7 2 0
Table 5. Distribution of HPV 16 and HPV 18 according to cervical intraepithelial neoplasia grades (CIN 1-3)
Tablica 5. Raspodjela HPV genotipova prema TLR9 polimorfizmu (rs352140)
Table 6. Allele frequencies of TLR9 polymorphisms
Tablica 6. U~estalosti alela TLR9 polimorfizama
TLR9 (rs187084) TLR9 (rs352140)
Nucleotide cytosine thymine cytosine thymine 
Allele frequency 0.39* 0.61* 0.51* 0.49* 
* Hardy-Weinberg equillibrum rs187084 and rs352140 
Figure 1. Prevalence of HR HPV genotypes among HR HPV positive women with cervical dysplasia and cervical grades CIN1-3
Slika 1. Prevalencija HR HPV genotipova u HR HPV pozitivnih ` ena s cervikalnom displazijom i cervikalnim stupnjevima (CIN 1-3) 
Risk factors and molecular predispositions for cervical dysplasia...
ing to cervical dysplasia (p=0.0539). In addition, HPV 16
genotype was more often found in cervical dysplasia com-
pared to HPV 18 genotype.
Prevalence of HR HPV genotypes among HR HPV
positive women with cervical dysplasia and cervical
grades CIN1-3
Figure 1 shows prevalence of HR HPV genotypes
among 97 positive CIN1-3 women. The most prevalent
HR HPV was HPV 16 (23.3 %) followed by HPV 31
(10.3 %), HPV 52 (8.9 %), HPV 51 (7.5 %), HPV 18 and
66 (6.2 % each), HPV 39 (5.5 %), HPV 56 and 59 (4.8 %
each), HPV 58 (4.1 %), HPV 33 and 53 (3.4 % each), HPV
73 (2.7 %), HPV 35, HPV 45 and 68 (2.1 % each), HPV 82
(1.4 %) and HPV 69 and HPV 70 (0.7 % each).
Distribution of allele frequencies of two SNPs of
TLR9 gene
Table 6 shows the distribution of allele frequencies
(-1486T/C, rs187084 and 2848C/T rs352140) in our study
population. Allele frequencies obtained from our study
were strictly similar to those obtained from HapMapCEU
study (ss68861046) where C-allele frequency is 0.34
while T-allele frequency is 0.66 for rs187084 while C-al-
lele frequency is 0.52 while T-allele frequency is 0.48 for
rs352140.
Discussion
HPV is a viral infection that is passed between people
through skin-to-skin contact. It is so common that most
sexually active people will get some variety of it at some
point, even if they have few sexual partners. It is impossi-
ble to know who will develop health problems from HPV,
but people with weakened immune systems may be more
at risk. However, there are some factors that specifically
increase a chance for HR HPV infection. Our study shows
that genital HPV infection in women is predominantly ac-
quired in adolescence, and peak prevalence in young adult
women (18 – 35). Researchers from all parts of the world
suggest largely different prevalence of HPV infection re-
lating age. Worldwide variations in HPV prevalence
across age appear to largely reflect differences in sexual
behavior across geographical regions [11]. But our analy-
sis showed no significant association with number of sexu-
al partners, probably due to smaller number of partici-
pants. The different incidence of HR HPV infection among
single and married women implicates that a stable marital
relationship protects against HPV infection [12]. The im-
pact of other risk factors, such as avoidance of condom use
and active tobacco smoking provides expected results. It is
generally thought that, in addition to carcinogenic effects
of cigarette smoke on cervical tissue [13], such as genotox-
ic DNA adducts [14] and the presence of mutagens in cer-
vical mucus [15], the excess risk may be mediated by its
effects on immunologic control of HPV infections [16].
Use of male condoms appears to reduce the risk of HPV
transmission from men to women, but provides far from
absolute protection. Some HPV infections are to be ex-
pected despite consistent condom use because the virus
can be spread by nonpenetrative genital contact [17]. The
rest of socioeconomic factors included in our research,
such as working status, monthly income, chronically dis-
eases or daily medicament use, showed no significant as-
sociation with HPV infection. However, some studies pre-
sent apparent connection between lower education, higher
poverty and potential HPV associated cancers [18].
Cellular and molecular studies over the past years have
identified a number of common TLR polymorphisms that
modify the cellular immune response and production of
cytokines. In addition, human genetic studies suggest that
some of these polymorphisms are associated with suscep-
tibility to a spectrum of conditions [19]. TLR9 variants
have been reported to have association with many infec-
tion and non-infection diseases. To our knowledge, this is
the first report on TLR9 polymorphisms and their correla-
tion with HR HPV cervical infection and cervical dyspla-
sia (CIN 1-CIN 3) in HR HPV positive patients from
Croatia. Our results have suggested that the investigated
two polymorphisms were not associated with HR HPV in-
fection and subsequently stages of cervical dysplasia. This
is similar to reports from several other researchers [20, 21]
that there are no consistent associations between polymor-
phism and infection risk, either overall or by type or
species. Some studies suggest that this correlation is only
marginal, as Pandey et al. showed that the TT genotype of
TLR9 (rs352140) displayed borderline significance in in-
creased risk for advanced cervical cancer in a North India
population [22]. Contrary to our study, association be-
tween TLR9 gene polymorphisms and HR HPV cervical
infection was found by the number of others, who claimed
that there is a strong connection between certain TLR9
polymorphisms and incidence of cervical dysplasia [23,
24, 25]. These differences in the effect of TLR9 polymor-
phism on the susceptibility to cervical cancer development
between these studies may result from racial heterogene-
ity, the size of the studied groups, and the action of distinct
behavioral and environmental factors [26]. The distribu-
tion of two TLR9 gene polymorphisms (-1486T/C,
rs187084 and 2848C/T rs352140) in 50 HR HPV negative
women and 100 HR HPV positive women from north-east
Croatia was comparable to that in European population
(the National Center for Biotechnology Information,
NCBI). As expected from previous studies, the two SNPs
in the TLR9 gene were in linkage disequilibrium.
Distribution of those two SNPs of TLR9 gene according to
HPV genotypes in HR HPV positive women show no asso-
ciation between HPV genotypes. There is no prevalence of
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a single HPV genotype among patients with TLR9 muta-
tion suggesting that it is not the virus responsible for muta-
tion. Similar findings are among other researchers [20],
while some present unquestionable connection of certain
polymorphism and HPV 16 infection [25]. The fact that
some SNPs are more prevalent in younger population (18 –
35 years old) may be due to increased exposure to different
HPV types, but the correlation between mutation and a
number of sexual partners does not support this hypothe-
sis. The association of certain polymorphism with HPV in-
fection is present only in homozygote variation, indicating
a complete mutation is necessary for influence on immune
system. What is the cause of TLR9 mutation is presently
unknown. We investigate its possible connection with so-
cial and environmental factors, but found no association.
However, it remains that specific TLR9 polymorphisms
could be a genetic risk factor for cervical cancer. Why
some SNPs have influence on HPV infection and some
not, is inconclusive. There may be some other genetic
component that affects baseline TLR expression which re-
sults in increased vulnerability to HPV infection of certain
population. The cervical vaginal microbiological and im-
munological milieu is extremely complicated and is affect-
ed by a host of environmental and genetic factors which
are at the moment beyond our reach [5].  
On the other hand, the distribution of cervical dyspla-
sia CIN1-CIN3 according to HPV 16 and HPV 18 cervical
infection show significant difference. HPV 16 genotype
was more often found in cervical dysplasia compared to
HPV 18 genotype. Such outcome is indisputable and
equivalent with other studies results [5, 9, 27, 28, 29]. HPV
16 is a member of the human alphapapillomavirus-9 group
[30] and has shown to confer a significantly higher risk of
developing high-grade CIN lesions or invasive cancers in
combination with other HPV types [31]. HPV 16 is the
most carcinogenic type among HR sub-group and inter-
feres with innate immunity by affecting the expression of
TLRs [9]. This can be explained by much potent influence
of HPV 16 protooncogenes comparatively to HPV 18.
Also, HPV 16 is able to evade immune recognition and this
evasion results in its persistence and indicating by the lack
of TLR expression increase in the persistence. Infection of
human primary keratinocytes with HPV 16 oncogenes E6
and E7 inhibits TLR9 transcription and leads toward func-
tional loss of TLR9-regulated pathways. In comparison,
E6 and E7 from HR HPV 18, which is known to persist less
competently in the host than HPV 16, have reduced effi-
ciency in inhibiting TLR9 transcription. The distribution
of allele frequencies (-1486T/C, rs187084 and 2848C/T
rs352140) in our study population were strictly similar to
those obtained from HapMap-CEU study (ss68861046)
where C-allele frequency is 0.34 while T-allele frequency
is 0.66 for rs187084 while C-allele frequency is 0.52 while
T-allele frequency is 0.48 for rs352140. Such allotment
suggests that polymorphisms of TLR signaling pathway
influence the cellular and molecular mechanisms of differ-
ent human diseases.
We analyzed distribution between TLR9 polymor-
phism (rs187084, -1486T/C) in the putative promoter re-
gion and synonymous TLR9 polymorphism (rs352140,
C2848T) in exon 2 and HPV positive and negative women
and their association with HPV cervical infection. No sig-
nificant difference between both TLR9 polymorphisms
(rs187084, rs352140) and cervical HPV infection was ob-
served. Martinez-Campos C et al. reported that genotype
TT in the -1486 locus of TLR9 was significantly associat-
ed with HPV infection among Mexican women. In present
study, genotype TT (63 %) at the same locus is the most
prevalent among HPV positive women, which indicates a
significant association between analyzed polymorphisms
of the TLR9 gene with HPV cervical infection [32].
Meta-analysis of the most intensively studied poly-
morphisms of TLR9 gene (rs187084, rs352140, and
rs5743836) reported that rs187084 polymorphism is asso-
ciated with increased risk of cervical cancer in Caucasians
but not in Asians, whereas rs352140 polymorphism is not
associated with any cancer risks neither in Caucasians or
Asians [33]. Those findings suggest that diversity between
studies could be explained by cancer-types specificity in
the positive studied participants and their different car-
cinogenetic mechanisms, undefined/incomparable fea-
tures of controls participants and relatively small sample
size. In addition, discrepancies in polymorphisms of TLR9
gene between ethnicities indicate a possible influence of
genetics and environmental factors (age, sex, smoking,
drinking etc.).
After HPV vaccination, microarray studies conducted
on HPV infected cells confirmed higher secretion of Th1
cytokines (IFN-γ and interleukin-2) and subsequently, due
to above mentioned down regulation of TLR9 receptors,
lack of Th1 immune response in HPV positive cervical
cells is highly associated with development of HPV cervi-
cal infection persistency [34] which contributes with im-
paired TLR9 signaling and malignant transformation [24].
Due to abolish transcription of TLR9 gene in HR HPV
infected cervical keratinocytes and other risk factors such
as active smoking, no condom usage and sexual behavior
(appeared) suggested that TT genotypes HR HPV positive
women from our study may have a greater risk for progres-
sion of CIN to cervical carcinoma. However, it should be
noted that the present study included low sample size and
therefore the results can be considered as preliminary.
It is clear that human variations on genetic level have a
strong impact on inflammation and disease susceptibility
[19] and host genetic factors of immune related genes may
explain the differences in the ability to clear the HPV in-
fection. Additional research has showed that functional
variants in xenobiotic metabolism genes have been associ-
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ated with cervical cancer risk [35]. Due to such hypothesis,
can host genetic factors associated with higher clearance
rate of HR HPV serve as a potential biomarker for future
HPV related disease [35]? Can it be exploit for therapeutic
approach? Is the strong immunologic response in HPV in-
fection desirable or the inflammation could result in DNA
damage, which could allow HPV to integrate? Studies
have shown that excess TNF-α can result in harmful in-
flammatory responses, whereas too little can contribute to
persistent infection. TNF-α is one of the primary cytokines
released after HPV infection and upregulates the expres-
sion of antigen-processing and presentation pathway com-
ponents for class I human leukocyte antigen (HLA) [36].
Has the polymorphism of certain proinflammatory cy-
tokine greater impact on HPV clearance than TLR9 poly-
morphism? A new association was reported between sev-
eral TNF polymorphisms and susceptibility to cervical
cancer [3]. Accumulative epidemiological evidence sug-
gests that polymorphisms of TLR signaling pathway light
up the cellular and molecular mechanisms of human dis-
eases who's gaining a primordial importance [37].
Currently, there is not enough evidence available to under-
stand whether specific infection or diseases are more or
less likely to be influenced by TLR polymorphisms.
Larger well-designed studies with precise clinical and mi-
crobiological phenotyping will be required to validate
these observations.
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